B Lymphocyte News and Research

RSS

ECTRIMS previews important sessions ahead of world’s largest annual congress of multiple sclerosis

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) previews the key sessions ahead of its annual congress – a dedicated platform to promote and enhance research in Multiple Sclerosis. The 32nd edition of the world’s largest congress of multiple sclerosis will take place in London from 14 – 17 September 2016.

17 Aug 2016

Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget.

12 Jul 2016

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.

12 Jul 2016

Scientists discover link between two genes involved in PD and autoimmune diseases

A study publish in the journal CELL indicates that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease.

27 Jun 2016

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Salsalate has no greater effect than placebo on the progression of coronary artery plaque, show the findings of the randomised TINSAL-CVD trial.

3 Jun 2016

Real risk of rebound syndrome following fingolimod cessation for MS

Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs.

4 May 2016

KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.

21 Apr 2016

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients. The finding could lead to new treatments for the chronic autoimmune disease, said researchers at Penn State College of Medicine.

12 Apr 2016

Newly developed computer models can simulate stem cell transplant recovery

Scientists at Virginia Commonwealth University have developed computer models that can simulate the recovery of the immune system in patients undergoing stem cell transplants.

18 Mar 2016

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study -- a 10-nation, randomized clinical trial of adult outpatients -- investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS.

18 Mar 2016

Neural stem cells from T cell-derived iPSCs provide neurological disease model

Researchers in Japan report that neural stem cells derived from readily available T cell-derived iPSCs provide a neurological disease model when cultured in a novel protocol developed by them. The findings are important for the treatment of Parkinson’s disease and are published in Stem Cell Reports, March 2016.

16 Mar 2016

New microfluidic biosensor can identify white blood cells quickly for AIDS diagnosis

Researchers from the University of Illinois at Urbana-Champaign have developed a highly sensitive biosensor based on a differential immuno-capture technology that can detect sub-populations of white blood cells. As part of a small, disposable biochip, the microfluidic biosensor can count CD4+/CD8+ T cells quickly and accurately for AIDS diagnosis in the field.

14 Mar 2016

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute.

7 Mar 2016

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL).

4 Mar 2016

Research: Adenosine deaminase may help activate immune system against HIV

New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug.

3 Feb 2016

MD Anderson signs collaborative research and development agreement with Enumeral

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.

12 Jan 2016

Researchers discover novel way to enhance, restore cancer suppressor activity in B-ALL

Researchers at Penn State College of Medicine, working with Chinese and American colleagues, have discovered a novel way to enhance and restore cancer suppressor activity in B-cell acute lymphoblastic leukemia, resulting in better outcomes in a pre-clinical model of the disease. The finding could pave the way for a new class of drugs for this and other forms of leukemia.

15 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015

Risk of developing visceral leishmaniasis much higher in transplant patients

Researchers from Spain have analysed the prevalence of leishmaniasis among the population of organ transplant recipients. The findings of this study, published in the journal 'PLoS Neglected Tropical Disease', confirm that the risk of developing visceral leishmaniasis ‑the most severe form of the disease which can pose life-threatening complications‑ is more than one hundred times greater in transplant patients living in areas of disease outbreak.

25 Nov 2015

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

29 Oct 2015